These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11122801)

  • 1. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
    Selman AE; Copeland LJ
    Curr Oncol Rep; 1999 Sep; 1(1):71-6. PubMed ID: 11122801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
    Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
    Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of CA 125 measurement before second-look laparotomy in patients with ovarian carcinoma.
    Hørding U; Toftager-Larsen K; Lund B; Dreisler A; Daugaard S; Lundvall F; Knudsen JB; Bock JE
    Eur J Gynaecol Oncol; 1994; 15(3):217-21. PubMed ID: 7957327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundant.
    Frasci G; Conforti S; Zullo F; Mastrantonio P; Comella G; Comella P; Persico G; Iaffaioli RV
    Cancer; 1996 Mar; 77(6):1122-30. PubMed ID: 8635133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of second-look laparotomy in the long-term survival in ovarian cancer.
    Tuxen MK; Strauss G; Lund B; Hansen M
    Ann Oncol; 1997 Jul; 8(7):643-8. PubMed ID: 9296216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
    Jäger W; Adam R; Wildt L; Lang N
    Arch Gynecol Obstet; 1988; 243(2):91-9. PubMed ID: 2456743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
    Sevinc A; Camci C; Turk HM; Buyukberber S
    Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical value of tumour markers in the management of ovarian cancer.
    Rustin GJ
    Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
    [No Abstract]   [Full Text] [Related]  

  • 9. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings].
    Meden H; Rath W; Teichmann A; Kuhn W
    Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
    Sugiyama T; Nishida T; Komai K; Nishimura H; Yakushiji M; Nishimura H
    Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K; Ghamande S; Chandrasekaran EV; Ta A; Moysich KB; Driscoll D; Matta K; Lele S
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
    Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
    Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the second-look laparotomy in the management of carcinoma of the ovary.
    Yakushiji M; Kato T
    Semin Surg Oncol; 1986; 2(2):72-5. PubMed ID: 3454039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?
    Byrom J; Widjaja E; Redman CW; Jones PW; Tebby S
    BJOG; 2002 Apr; 109(4):369-75. PubMed ID: 12013156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure.
    Folk JJ; Botsford M; Musa AG
    Gynecol Oncol; 1995 May; 57(2):178-82. PubMed ID: 7729730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Bendifallah S; Body G; Daraï E; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
    García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
    Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
    Markowska J; Wilkoszarska J; Emerich J; Debniak J; Popiela A; Pańszczak M; Kornafel J; Rossochacka B; Fisher Z; Goluda M; Małecki P
    Eur J Gynaecol Oncol; 2000; 21(2):164-7. PubMed ID: 10843477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma.
    Lund B; Williamson P
    Obstet Gynecol; 1990 Oct; 76(4):617-22. PubMed ID: 2216190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
    Low RN; Duggan B; Barone RM; Saleh F; Song SY
    Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.